Drug Type Synthetic peptide |
Synonyms DACRA-042, UGP-302 |
Target |
Mechanism AMYR agonists(Amylin receptor agonists), CALCR agonists(Calcitonin receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC149H246N44O48S2 |
InChIKeyWGPKKADKWIWSCQ-XTWYBNIISA-N |
CAS Registry1432581-36-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | CZ | 23 Aug 2017 | |
Diabetes Mellitus, Type 2 | Phase 2 | DK | 23 Aug 2017 | |
Diabetes Mellitus, Type 2 | Phase 2 | MD | 23 Aug 2017 | |
Diabetes Mellitus, Type 2 | Phase 2 | PL | 23 Aug 2017 | |
Diabetes Mellitus, Type 2 | Phase 2 | RO | 23 Aug 2017 | |
Diabetes Mellitus, Type 2 | Phase 2 | GB | 23 Aug 2017 | |
Obesity | Discovery | DK | 22 Jun 2013 |
Not Applicable | - | innarmjmyp(dtetdlyfxs) = osrmepxtcv dmagkscyws (olccchkrgy ) | Positive | 26 Sep 2013 | |||
sCT | innarmjmyp(dtetdlyfxs) = jqkyeyzyfs dmagkscyws (olccchkrgy ) | ||||||
Not Applicable | - | xjzrjgdbyj(emzwlkwxgt) = huyluarsnz mosgakiqxu (fvgtsndrga ) | - | 25 Sep 2013 | |||
xjzrjgdbyj(emzwlkwxgt) = cgqqeqrbxc mosgakiqxu (fvgtsndrga ) |